Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHiR Regimen for Elderly Newly Diagnosed DLBCL
NCT06764017Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Ningbo University
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat, zanubrutinib and lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital of Ningbo University. Primary endpoint: Complete Remission Rate. Started Feb 2025; status: recruiting.
02
Drugs
tucidinostatzanubrutiniblenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06764017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06764017.